David Mohan, MD
Family Medicine · Fort Wayne, INNPI 1578876785
Payments from drug & device makers
Across 570 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$1K
- Sanofi-aventis U.S. LLC$1K
- AbbVie$696
- Amgen$661
- Boehringer Ingelheim$591
- plus $3K from 27 others
What the payments were for
- Food & beverage$9,225100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 85 | $1,793 |
| Lilly USA, LLC | 68 | $1,076 |
| Sanofi-aventis U.S. LLC | 67 | $1,042 |
| AbbVie(2 entities) | 49 | $696 |
| Amgen | 45 | $661 |
| Boehringer Ingelheim | 31 | $591 |
| GSK | 42 | $567 |
| Novo Nordisk | 44 | $532 |
| Pfizer | 25 | $358 |
| Amarin Pharma, Inc. | 17 | $270 |
| Exact Sciences | 12 | $199 |
| Merck | 11 | $180 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $165 |
| Astellas Pharma US Inc | 9 | $154 |
| Novartis | 8 | $152 |
| Boston Scientific | 8 | $149 |
| Abbott | 5 | $75 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Kowa Pharmaceuticals America, Inc. | 3 | $59 |
| Harmony Biosciences LLC | 3 | $57 |
| Eisai Inc. | 3 | $56 |
| Corcept Therapeutics | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Bayer | 2 | $38 |
| Johnson & Johnson | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Medtronic | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$104
How this compares
$9,225 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf)Adalimumab | 20 | $181,504 |
| TradjentaLinagliptin | 97 | $112,908 |
| JardianceEmpagliflozin | 84 | $96,517 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 64 | $78,181 |
| JanuviaSitagliptin Phosphate | 56 | $77,571 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $71,010 |
| FarxigaDapagliflozin Propanediol | 48 | $64,869 |
| EliquisApixaban | 62 | $61,800 |
| OzempicSemaglutide | 48 | $57,831 |
| TrulicityDulaglutide | 37 | $55,830 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $52,140 |
| VascepaIcosapent Ethyl | 55 | $44,203 |
| RybelsusSemaglutide | 13 | $31,957 |
| XareltoRivaroxaban | 23 | $27,453 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $26,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance, Stiolto Respimat | $591 | $215,546194 claims |
| AbbVieHumira(Cf), Restasis, Synthroid | $696 | $192,89482 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $567 | $90,068111 claims |
| Novo NordiskOzempic, Rybelsus | $532 | $89,78961 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,793 | $84,19598 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,042 | $78,18164 claims |
| MerckJanuvia | $180 | $77,57156 claims |
| PfizerEliquis | $358 | $61,80062 claims |
| Lilly USA, LLCTrulicity | $1,076 | $55,83037 claims |
| Johnson & JohnsonXarelto | $34 | $27,45323 claims |
| NovartisEntresto | $152 | $10,46116 claims |
| Astellas Pharma US IncMyrbetriq | $154 | $8,09413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Fort Wayne
- Thomas KintanarFort Wayne$185K
- Brianna SerbusFort Wayne$174K
- Brian AdamsFort Wayne$173K
- Charles CoatsFort Wayne$38K
- Beulah PenumudiFort Wayne$38K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.